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2001 and 2002, when early primary prevention ICD trials such as
MADIT (Multicenter Automatic Defibrillator Implantation
Trial) and MUSTT (Multicenter UnSustained Tachycardia Trial)
were being digested and accepted by the scientific community. It
remains unsettled, however, whether ICDs confer a higher infec-
tion risk than PMs (3,4). An indirect effect of expanding ICD
indications could be an increased proportion of implantation by
low volume operators or facilities, a factor that has been linked to
higher rates of mechanical complications and infections (5).
However, this probability cannot be tested using the NHDS
database. It is also possible that greater physician awareness and
improvements in detection and reporting of device-related infec-
tions have contributed to the rise over the study period. Regardless
of the cause, the disproportionate rise in CRMD-related infections
carries significant public health consequences, and further study is
warranted to confirm this trend and to elucidate its causes.
In addition to its morbidity and associated additional health
care resource expenditures, CRMD infection confers high in-
hospital mortality rates. In the late 1990s, Chua et al. (6)
retrospectively studied 117 patients undergoing device extraction
for CRMD infection at a large tertiary care center and found low
all-cause and zero-operative mortality. The recent expansion of
ICD and cardiac resynchronization therapy to patient populations
with a heavier burden of cardiovascular disease may explain the
higher mortality seen with CRMD infection in this analysis.
This study has several important limitations. The NHDS
database, though providing broad national representation, lacks
detailed clinical information. Thus, determination of the mode of
in-hospital death, the specialty of the implanting physicians, and
the identification of the offending organisms are not within the
scope of the NHDS. The validity of the data hinges upon
appropriate coding of ICD-9-CM codes at the time of hospital
discharge. We cannot exclude changes in coding patterns over the
8 years of the study period, for example to improve Medicare
reimbursement for certain diagnoses. Because the NHDS records
hospitalizations, but does not identify individual patients, the true
incidence of CRMD infection cannot be determined.
In conclusion, our results demonstrate a rapid rise in rates of
hospitalization for CRMD-related infection in the U.S. in the
years 2001 through 2003, the last year for which data is currently
available. This morbid and costly complication of CRMD therapy
can be lethal, as evidenced by its associated high rates of in-
hospital mortality. Further research should be undertaken to
confirm these findings, determine the causes of rising rates of
CRMD infections, and to improve therapeutic options for these
important adverse events.
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Letters to the Editor
Questions in
Cardiac Resynchronization
Therapy: Metabolic Implications
With great interest we read the study by Bax et al. (1) relating to
unresolved questions of cardiac resynchronization therapy (CRT).
Many different trials have shown the beneficial effects of CRT
using a variety of quantitative assessments such as the 6-min walk
test, peak oxygen consumption (VO2), New York Heart Associa-
tion (NYHA) functional class, quality-of-life measures, or mor-
tality as primary end points. Among the exercise test variables,
ventilatory efficiency (VE/VCO2) slope is increasingly recognized as
at least as good and possibly an even better prognostic indicator
than peak VO2 (2). Does CRT improve VE/VCO2 slope? So far
only one uncontrolled study has addressed this question, and after
1 to 3 months no improvement was seen. A large body of evidence
shows that chronic heart failure (CHF) affects skeletal muscle
functional capacity and metabolic status (like increased insulin
resistance [3]), which in turn contribute to patient symptoms.
Information on changes of these parameters with CRT would be
relevant in order to shed more light on the mechanisms of
CRT-related improvement of symptomatic status. In CHF pa-
Table 1. Multivariate Predictors of In-Hospital Mortality in
Patients With Cardiac Rhythm Management Devices
OR
95% CI
p ValueLower Upper
Age per 20-yr increase 1.63 1.41 1.89 0.001
Female gender 0.86 0.72 1.03 0.11
Race minorities vs. Caucasians 1.12 0.85 1.48 0.42
Diabetes mellitus 1.03 0.81 1.31 0.82
Renal failure 1.76 1.26 2.47 0.001
Type of device implanted
(ICD vs. PM)
0.78 0.55 1.11 0.17
Hospital size (per 100-bed
increase in size)
1.04 0.97 1.12 0.26
CRMD infection 2.41 1.58 3.66 0.001
CI  confidence interval; CRMD  cardiac rhythm management device; ICD 
implantable cardioverter-defibrillator. OR  odds ratio; PM  pacemaker.
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tients a lower body mass index and a decrease in body weight are
associated with worse outcome (4). Treatments that are clearly
beneficial in CHF have also been shown to prevent weight loss
(angiotensin-converting enzyme inhibitors and beta-blockers [4])
or even increased body fat mass (beta-blockers) (5). Until today
there are no data on changes in body weight or body composition
following CRT. We agree with Bax et al. (1) that much more
research remains to be done regarding CRT. We believe that
metabolic pathways should be an important focus of these inves-
tigations. This will promote our understanding of the pathophys-
iology of CHF and of the response to CRT and may help to better
guide patient selection for cardiac resynchronization therapy.
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REPLY
We thank Dr. Karhausen and colleagues for their constructive
comments concerning our manuscript of the unresolved issues in
cardiac resynchronization therapy (CRT) (1). As the researchers
point out, there are many such issues concerning CRT. The most
difficult issue remains the prediction of response to CRT (2). It has
become evident that the current selection criteria are not sufficient,
as 20% to 30% of patients do not respond to CRT. The most
promising techniques to better select the potential responders are
the different sophisticated tissue Doppler imaging (TDI) tech-
niques. However, as pointed out in part 1 of our review on CRT
(2), many techniques have been proposed. In total, 24 studies with
TDI to predict response to CRT have been published; only 2 (8%)
demonstrated that interventricular dyssynchrony was useful to
predict response, whereas all 24 studies demonstrated some value
of intraventricular (within the left ventricle) dyssynchrony for the
prediction of response to CRT. How to precisely assess the
intraventricular dyssynchrony is currently not clear, and the extent
of dyssynchrony (in ms) needed to result in response to CRT is
also uncertain.
Moreover, this uncertainty is further complicated by the fact
that a precise definition of a responder to CRT is lacking. As
emphasized by Dr. Karhausen and colleagues, various end points
have been used. In addition, a single patient may show improve-
ment in a certain end point, but not in another end point. This has
been highlighted recently by Bleeker et al. (3) showing a discrep-
ancy between improvement in clinical markers and echocardio-
graphic markers in patients undergoing CRT.
Finally, Dr. Karhausen and colleagues raise an even more
complicated issue, namely changes in metabolic status after CRT.
Indeed, this is a very important concern, and data on this topic are
virtually nonexistent. We fully agree with Dr. Karhausen and
colleagues that more work is needed, including in the field of
metabolic response to CRT.
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Allergic Reactions Following
Implantation of Drug-Eluting Stents:
A Manifestation of Kounis Syndrome?
In the very interesting study (1) and editorial (2) published in the
January 3, 2006 issue of the Journal, the investigators reported and
commented on 17 patients who developed allergic reactions after
implantation of drug-eluting stents (DES). These reactions in-
cluded rash, hives, itching, dyspnea, and fever. However, four
patients developed in-stent thrombosis and died at 4, 5, 18, and 18
months after implantation, respectively. Eosinophilia and elevated
immunoglobulin E (IgE) titers accompanied the allergic reactions.
One patient had implanted a TAXUS (Boston Scientific Corp.,
Natick, Massachusetts) stent impregnated with the antineoplastic
agent paclitaxel, and the other three had CYPHER (Cordis Corp.,
Miami Lakes, Florida) stents impregnated with the anti-
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